Long-term follow-up and secondary malignancy in mycosis fungoides patients treated by electron beam irradiation.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18511-e18511
Author(s):  
Miroslav Lutsyk ◽  
Orit Kaidar-Person ◽  
Micha Bar-Hanna ◽  
Yoram Cohen ◽  
Abraham Kuten
Keyword(s):  
Electron Beam ◽  
Mycosis Fungoides ◽  
Electron Beam Irradiation ◽  
Secondary Malignancy ◽  
Secondary Malignancies ◽  
Beam Irradiation ◽  
Photon Irradiation ◽  
Long Term Follow Up

e18511 Background: Mycosis fungoides (MF) and Sezary's syndrome are the most common subgroup of cutaneous T-cell lymphoma. Total or partial skin electron beam irradiation (TSEI, PSEI) is an accepted treatment option in cases of disease that is limited to the skin and as palliative treatment in advanced disease. Consequently, long term follow-up of these patients and detection of secondary malignancies after TSEI/PSEI is crucial. The aim of this study was to summarize long term follow-up of MF patients treated by TSEI or PSEI and to evaluate the rates of secondary malignancies. Methods: A retrospective review of the medical charts of all consecutive patients diagnosed with MF who was treated from January 1960 to June 2010 at our hospital was conducted. Data collected included demographics, date of diagnosis, staging, treatment, and secondary malignancies. Results: One hundred ninety six patients were included (132 M, 64 F). The median age at diagnosis was 67.3 years. The mean follow-up was 109.4±89.4 months (range 1-566). One hundred patients received TSEI, 45 patients received PSEI, and one patient was treated by low dose total body photon irradiation combined with TSEI. Fifty patients (50/196, 25.5%) developed a second malignancy, 16 patients (16/196, 8%) had a third malignancy, and 4 (2%) patients developed a fourth malignancy. Conclusions: MF is associated with development of sequential malignancies. The contribution of TSEI or PSEI to the development of secondary malignancies is yet to be determined. Long term follow-up in this group of patients is essential.

scholarly journals PO-1091: Total skin electron beam irradiation in mycosis fungoides. Long-term results

2018 ◽  
Vol 127 ◽  
pp. S614
Author(s):  
R. Benlloch Rodríguez ◽  
I. Zapata Paz ◽  
R. Rodríguez Romero ◽  
B. Vaquero Barrón ◽  
V. García Jarabo ◽  
...  
Keyword(s):  
Electron Beam ◽  
Mycosis Fungoides ◽  
Electron Beam Irradiation ◽  
Long Term Results ◽  
Beam Irradiation

scholarly journals Long-Term Medical Follow-Up (for More than 15 Years) of a Patient with Stage IA Mycosis Fungoides Originally Presenting in Childhood: Remission for >15 Years with Localised Electron Beam Therapy

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Eric Bessell ◽  
Martin Dalton ◽  
John David Parry
Keyword(s):  
Electron Beam ◽  
Mycosis Fungoides ◽  
World Literature ◽  
Complete Regression ◽  
Specialist Care ◽  
Electron Beam Therapy ◽  
Long Term Follow Up ◽  
Stage Ia

A man now aged 80 years has received specialist care for stage 1A mycosis fungoides for 58 years. The disease developed in childhood. Long-term follow-up (>30 years) of patients with mycosis fungoides is infrequently described in the world literature. The disease in this patient was limited to 5 areas, but these were large (up to 25 cm in diameter). The rest of the skin was normal clinically. All 5 areas were treated separately with electron beam therapy (3–4 MeV) to a dose of 30 Gy in 15 fractions over 3 weeks between 2000 and 2005. Complete regression was obtained in all 5 areas, and the patient has been in complete remission for 15 years after living with the disease previously for over 40 years.

scholarly journals Disseminated Cutaneous Cytomegalovirus Infection Following Total Body Electron Beam Irradiation for Mycosis Fungoides

2015 ◽  
Vol 151 (12) ◽  
pp. 1380 ◽  
Author(s):  
Julie K. Kim ◽  
Adeel Ahmad ◽  
M. Angelica Selim ◽  
Elise A. Olsen ◽  
Adela R. Cardones
Keyword(s):  
Electron Beam ◽  
Mycosis Fungoides ◽  
Cytomegalovirus Infection ◽  
Electron Beam Irradiation ◽  
Beam Irradiation ◽  
Total Body

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2925-2925 ◽  
Author(s):  
Ricardo Spielberger ◽  
Christos Emmanouilides ◽  
William Bensinger ◽  
Alan Rong ◽  
Alessandra Cesano ◽  
...  
Keyword(s):  
Controlled Study ◽  
Secondary Malignancies ◽  
Double Blind ◽  
Term Survival ◽  
Hematopoietic Stem ◽  
Double Blind Placebo ◽  
Disease Outcomes ◽  
Long Term Follow Up

Abstract Oral mucositis (OM) is a severely debilitating side effect of chemoradiotherapy that often causes significant pain, diminished quality of life, and increased risk of infections. Palifermin decreases the incidence and duration of severe OM in HM pts receiving myelotoxic therapy and HSCT. Palifermin safety and efficacy have not been established in the non-HM setting. Since the rHuKGF receptor is not expressed by HM, palifermin is not expected to interfere with long-term disease outcomes in this pt population. Aim: We assessed palifermin’s effects on the long-term disease outcomes (survival, disease progression, secondary malignancies) in pts with HM. Methods: Long-term follow-up data were pooled from a 1998 phase 2, double-blind, placebo-controlled study (n=86) and a 2000 double-blind, placebo-controlled phase 3 study (n=212). The analysis included 152 pts treated with palifermin and 146 pts treated with placebo. Pts were assessed at 6-month intervals during the first year and annually thereafter until death or loss to follow-up. The Kaplan-Meier (K–M) method provided estimates of the safety endpoints. Data reported here are as of August 2004. Results: There were 298 pts (152 palifermin: 146 placebo) monitored for long-term follow-up. The median follow-up period was 23.3 months for palifermin and 23.5 months for placebo. The overall survival and progression-free survival curves (p=0.474 and p=0.253, respectively) are similar between the palifermin and placebo groups. Secondary malignancies occurred in only 6 of 152 (3%) palifermin and 5 of 146 (4%) placebo pts. All secondary malignancies were myelodysplastic syndromes: 9 patients with diagnoses of Non-Hodgkin’s lymphoma and 2 patients of Hodgkin’s Disease. The number of deaths was similar between the groups (30% palifermin; 27% placebo); most deaths occurred within 12 months of randomization and were attributable to the underlying HM disease. Conclusion: Use of palifermin for the prevention of severe OM has shown no negative impact on long-term disease outcomes, including survival, in the HSCT setting for patients with HM.

Long-Term Follow-Up of BEACOPPescalated Chemotherapy in Patients with Advanced-Stage Hodgkin Lymphoma on Behalf of the German Hodgkin Study Group.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 211-211
Author(s):  
Engert Andreas ◽  
Jeremy Franklin ◽  
Volker Diehl
Keyword(s):  
Hodgkin Lymphoma ◽  
Secondary Malignancy ◽  
Tumor Control ◽  
Study Group ◽  
Advanced Stage ◽  
Secondary Aml ◽  
German Hodgkin Study Group ◽  
Long Term Follow Up

Abstract The HD9 trial of the German Hodgkin Study Group (GHSG) compared two different doses (baseline and escalated) of the novel chemotherapy regimen BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in patients with advanced-stage Hodgkin lymphoma (HL). The previous analysis with a median follow-up of 5 years showed improved tumor control (FFTF) and overall survival (OS) for BEACOPPescalated. Since BEACOPPescalated had been associated with more toxicity as compared with ABVD we report the results of long-term follow-up of 1196 patients enrolled and randomized in that study. The median follow-up was 112 months; a total of 370 centres contributed. Patients received one of three chemotherapy regimens: 8 cycles of COPP (cyclophosphamide, vincristine, procarbazine, and prednisone) alternating with ABVD (doxorubicin, bleomycin, vinblastin, and dacarbazine), 8 cycles of standard-dose BEACOPP or 8 cycles of escalated-dose BEACOPP. At 10 years, FFTF rates were 64%, 70% and 82%, OS rates were 75%, 80%, and 86 for COPP-ABVD (arm A), BEACOPPbaseline (arm B), and BEACOPPescalated, respectively (p < 0,001). Importantly, BEACOPPescalated was also significantly better than BEACOPPbaseline in terms of FFTF (p < 0.0001) and OS (p = 0.0053). Death due to HL occurred in 11.5%, 8.1% and 2.8% in arms A, B, and C, respectively. 74 second malignancies were documented, including secondary acute myeloid leukaemias (1,7,14), Non-Hodgkin lymphoma (7,8,5), and solid tumors (7,16,9) in arms A, B, and C respectively. The corresponding overall secondary malignancy rates were 6.7%, 8.9% and 6.8%. Importantly, the risk of secondary AML (sAML), although increased in this study after BEACOPPescalated, amounts to 0.9% in our follow-up study with BEACOPPescalated (HD12) in 1502 advanced-stage HL patients randomized and four years median follow-up. Although the higher rate of secondary AML after BEACOPPescalated in HD9 most likely occurred by chance, interestingly, 70% of patients in this group had additional radiotherapy whereas only 39% were radiated in HD12. Taken together, the 10 years follow-up of BEACOPPescalated chemotherapy demonstrates a stabilized significant improvement in long-term FFTF and OS for advanced-stage HL. Although for formal prove the results of ongoing prospective randomized comparisons with 8 cycles of ABVD might be required, these results clearly challenge ABVD as standard of care for this patient population.

Sign in / Sign up

Export Citation Format

Share Document